243 related articles for article (PubMed ID: 27486817)
1. Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.
Heery CR; Madan RA; Stein MN; Stadler WM; Di Paola RS; Rauckhorst M; Steinberg SM; Marté JL; Chen CC; Grenga I; Donahue RN; Jochems C; Dahut WL; Schlom J; Gulley JL
Oncotarget; 2016 Oct; 7(42):69014-69023. PubMed ID: 27486817
[TBL] [Abstract][Full Text] [Related]
2. Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
Autio KA; Pandit-Taskar N; Carrasquillo JA; Stephenson RD; Slovin SF; Rathkopf DE; Hong C; Heller G; Scher HI; Larson SM; Morris MJ
Cancer; 2013 Sep; 119(17):3186-94. PubMed ID: 23765638
[TBL] [Abstract][Full Text] [Related]
3. Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Pastina I; Lorenzoni A; Cianci C; Federici F; Mazzarri S; Orlandini C; Francesca F; Selli C; Ricci S; Rubello D; Mariani G
Nucl Med Commun; 2014 Jan; 35(1):88-94. PubMed ID: 24157942
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
Fizazi K; Beuzeboc P; Lumbroso J; Haddad V; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Theodore C; Loriot Y; Tournay E; Bouzy J; Laplanche A
J Clin Oncol; 2009 May; 27(15):2429-35. PubMed ID: 19364971
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
Morris MJ; Pandit-Taskar N; Carrasquillo J; Divgi CR; Slovin S; Kelly WK; Rathkopf D; Gignac GA; Solit D; Schwartz L; Stephenson RD; Hong C; Delacruz A; Curley T; Heller G; Jia X; O'Donoghue J; Larson S; Scher HI
J Clin Oncol; 2009 May; 27(15):2436-42. PubMed ID: 19364960
[TBL] [Abstract][Full Text] [Related]
6. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Dolezal J; Vizda J; Odrazka K
Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
[TBL] [Abstract][Full Text] [Related]
8. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).
McNeel DG; Chen YH; Gulley JL; Dwyer AJ; Madan RA; Carducci MA; DiPaola RS
Hum Vaccin Immunother; 2015; 11(10):2469-74. PubMed ID: 26111351
[TBL] [Abstract][Full Text] [Related]
10. Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?
Waldert M; Klatte T; Remzi M; Sinzinger H; Kratzik C
World J Urol; 2012 Apr; 30(2):233-7. PubMed ID: 21559805
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis.
Vigna L; Matheoud R; Ridone S; Arginelli D; Della Monica P; Rudoni M; Inglese E; Brambilla M
Phys Med; 2011 Jul; 27(3):144-52. PubMed ID: 20864370
[TBL] [Abstract][Full Text] [Related]
12. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
Chakraborty M; Wansley EK; Carrasquillo JA; Yu S; Paik CH; Camphausen K; Becker MD; Goeckeler WF; Schlom J; Hodge JW
Clin Cancer Res; 2008 Jul; 14(13):4241-9. PubMed ID: 18594006
[TBL] [Abstract][Full Text] [Related]
13. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
15. High-dose treatment with (186)Re-HEDP or (153)Sm-EDTMP combined with amifostine in a rabbit model.
Brenner W; Kampen WU; von Forstner C; Brümmer C; Zuhayra M; Muhle C; Czech N; Henze E
J Nucl Med; 2001 Oct; 42(10):1545-50. PubMed ID: 11585871
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
[TBL] [Abstract][Full Text] [Related]
17. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
18. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
Jong JM; Oprea-Lager DE; Hooft L; de Klerk JM; Bloemendal HJ; Verheul HM; Hoekstra OS; van den Eertwegh AJ
Eur Urol; 2016 Sep; 70(3):416-26. PubMed ID: 26391636
[TBL] [Abstract][Full Text] [Related]
19. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA
Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]